26 Landsdowne Street
169 articles about Fulcrum Therapeutics
Fulcrum Therapeutics Raises $80 Million Series B From Investors, Including Sanofi and Bill Maris'...
9/5/2018Fulcrum Therapeutics, based in Cambridge, Massachusetts, closed on an $80 million Series B financing.
Fulcrum Therapeutics Announces Additional Series A Financing From GV
Fulcrum Therapeutics Expands Leadership Team With Appointment Of Owen Wallace, Ph.D., As Chief Scientific Officer And Amit Hasija As Chief Business Officer
Fulcrum Therapeutics Strengthens Its Board Of Directors With The Addition Of Alan Ezekowitz, MBChB, D.Phil., And James J. Collins, Ph.D.
What You Need to Know About Fulcrum Therapeutics
BioSpace is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014.
Fulcrum Therapeutics Appoints Renowned Experts In CNS Disorders And Muscular Dystrophies To Serve On Newly Formed Scientific Advisory Board
Horizon Discovery Ltd. And Fulcrum Therapeutics Form Collaboration For Novel CRISPR-Based Target Discovery In Genetic Diseases
Former Epizyme CEO Helms Fulcrum Therapeutics; New Startup Banks $55 Million Series A